Uterine Cervical Dysplasia Clinical Trial
Official title:
Effectiveness of HPV Vaccine Among Women Age Equal or More Than 20 Years
- Background: The majority of the burden of HPV-related cervical cancer is in developing countries while most of the effectiveness reports of HPV vaccination are currently coming from developed countries. Also, currently many adult women are left without either HPV vaccination or cervical cancer screening. Effectiveness data of currently available HPV vaccines among adult women in developing countries are needed for women and healthcare workers and policy makers to best protect women from cervical cancer. - Primary Study Objective: - To determine the effectiveness bivalent and quadrivalent HPV vaccines in reduction of cervical dysplasia (Low-grade Squamous Intraepithelial Lesion or worse; LSIL+) attributable to HPV types 16 or 18 after at least 5 years of vaccination among Thai women vaccinated at their ages 20-45 years with at least one dose of the HPV vaccine - Secondary Study Objectives: - To measure the effectiveness of currently available bivalent and quadrivalent HPV vaccines in reducing the prevalence of HPV 16 or 18 - To measure the effectiveness of HPV vaccines in reducing any abnormal Pap smear result (ASC-US+) - To compare the effectiveness of HPV vaccines according to the number of doses immunized - To find out risk factor(s) for HPV 16 or 18-related cervical dysplasia in this cohort - To assess the prevalence of other high-risk HPV types in vaccinated and non-vaccinated group - To determine direct and/or indirect cost of HPV vaccination - The hypothesis to be tested: At least one dose of vaccination with bi- or quadri-valent HPV vaccine will reduce the prevalence of LSIL+ attributable to HPV 16/18 by 80% after at least 5 years of vaccination. - Materials and Methods: This study will be a retrospective matched cohort study. Data is to be collected either by from samples for Pap and HPV test and/or HPV 16/18 genotyping of the recruited participants, or from existing medical records. HPV vaccinated women at their ages 20-45 years (vaccinated group) and women received Pap smear at their ages 20-45 years without vaccination (control group) will be included in the study. Pap smear and HPV test and/or HPV 16/18 typing result of 2 groups will be compared after ≥ 5 years of vaccination or baseline Pap smear. Those who don't have Pap smear results ≥ 5 years after vaccination or ≥ 5 years after the baseline Pap smear will be offered for a Pap smear and HPV 16/18 typing
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01505920 -
Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial
|
Phase 3 | |
Completed |
NCT01014026 -
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
|
Phase 3 | |
Completed |
NCT00377845 -
Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
|
Phase 0 | |
Completed |
NCT02910388 -
LLETZ Under Direct Colposcopic Vision
|
N/A | |
Completed |
NCT00596258 -
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
|
Phase 2 | |
Completed |
NCT04415840 -
Lugol's Solution in Addition to Acetic Acid During Colposcopy
|
||
Recruiting |
NCT04783805 -
Conservative Management of HSIL in Patients With Future Pregnancy Aspiration
|
||
Completed |
NCT04326049 -
LLETZ With Videocolposcopy Versus LLETZ With Binocular Colposcopy
|
N/A | |
Completed |
NCT02486471 -
Hemostatic Procedure After Biopsy of the Cervix
|
N/A | |
Completed |
NCT02515162 -
Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization
|
N/A | |
Completed |
NCT01405768 -
Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)
|
Phase 2 | |
Completed |
NCT00264732 -
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix
|
Phase 2/Phase 3 | |
Completed |
NCT03296566 -
The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams
|
N/A | |
Completed |
NCT02346227 -
Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix
|
Phase 3 | |
Completed |
NCT02330471 -
Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial
|
Phase 3 | |
Completed |
NCT01035580 -
Trial on Safety and Pharmacokinetics of Intravaginal Curcumin
|
Phase 1 | |
Completed |
NCT01639820 -
Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts
|
N/A | |
Completed |
NCT00285207 -
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
|
Phase 2 | |
Recruiting |
NCT05225493 -
HIV Indicator Diseases in Hospital and Primary Care
|
||
Completed |
NCT01034358 -
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
|
Phase 4 |